Thursday, October 22, 2026 Published by AdvancedCare USA Inc.

TheraNews
Subscribe

Archive summary Clinical & research

Psychedelicnewsbreaks Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress On Ketamine NDA And HOPE Clinic Rollup

NRx Pharmaceuticals (NASDAQ: NRXP) reported a Q1 2025 net loss of $5.5 million, down from $6.5 million in the same period last year, with operating losses narrowing ...

Summary of reporting by menafn 1 min read Markdown

Psychedelicnewsbreaks Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q1 Results, Highlights Progress On Ketamine NDA And HOPE Clinic Rollup

Originally reported by menafn. Read more

Source: https://menafn.com/1111026582/Psychedelicnewsbreaks-Nrx-Pharmaceuticals-Inc-NASDAQ-NRXP-Reports-Q1-Results-Highlights-Progress-On-Ketamine-NDA-And-HOPE-Clinic-Rollup

Newsletter

The weekly digest

Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.